Figure 4 New PET radiotracers in lymphoma

Slides:

Advertisements

Similar presentations

ROLE OF FDG-PET/CT STUDY IN THE DETECTION OF BONE MARROW DISEASE IN PATIENTS WITH AGGRESSIVE NON- HODGKIN LYMPHOMA (NHL) AND HODGKIN LYMPHOMA (HL) Figure.

Advertisements

Fig FDG PET-CT in patient with cutaneous T-cell lymphoma with treatment response. Baseline (A) and post treatment (B) axial fused PET-CT images demonstrate.

Nat. Rev. Neurol. doi: /nrneurol

FDG PET-CT of Genitourinary and Gynecologic Tumors: Overcoming the Challenges of Evaluating the Abdomen and Pelvis Leslie K. Lee, MD, Aoife Kilcoyne,

Nat. Rev. Urol. doi: /nrurol

Hugo J.A. Adams, Rutger A.J. Nievelstein, Thomas C. Kwee Blood Reviews

Figure 1. A: T1-weighted MRI shows enhanced lesion with peripheral edema on left frontal area, compatible with high grade glioma. B: Left frontal area.

Staging of diffuse large B-cell lymphoma (DLBCL)

How I treat extramedullary myeloma

First Experience of Imaging Large Vessel Vasculitis With Fully Integrated Positron Emission Tomography/MRI by Ingo Einspieler, Klaus Thürmel, Matthias.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Figure 1 Concept of the therapeutic index

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 3 Risk-adapted and response-adapted

Figure 2 New functional imaging techniques in lymphoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

7.1b. Contrast coronal T1 Wtd MRI 7.1c. Contrast sagittal T1 Wtd MRI

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 4 Neuromyelitis optica spectrum disorder brain lesions

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 CAR-T-cell design

Figure 2 The association between CD8+ T‑cell density of the tumour

Jasmin JO and David Schiff

Figure 1 Clinical case study

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Urol. doi: /nrurol

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 1 Evolution of multiple sclerosis

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Treatment of 7 patients with relapsed/refractory NK/T-cell lymphomas treated with pembrolizumab. Treatment of 7 patients with relapsed/refractory NK/T-cell.

Figure 4 11C-PK11195-PET scans showing the evolution of neuroinflammation in a patient after stroke Figure 4 | 11C-PK11195-PET scans showing the evolution.

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Nat. Rev. Urol. doi: /nrurol

Figure 1 Tau PET images in patients with Alzheimer disease

MR-PET of the body: Early experience and insights

Chapter 16 Neurologic Dysfunction and Kidney Disease

In 507 follow-up images, only 1

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Frequency of lesions detected using CNS imaging (computed tomography [CT] and magnetic resonance imaging [MRI]) on patients with baylisascariasis (see.

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Cerebral and spinal MRI (A) Restricted diffusion of both optic nerves (arrows) on diffusion-weighted and apparent diffusion coefficient imaging.

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Off-midline sagittal T1-weighted MR image (600/12/1) in a 63-year-old man with newly diagnosed non-Hodgkin lymphoma shows diffusely abnormal diploic marrow.

Figure Serial brain MRI of the patient with encephalitis and spontaneous recovery accompanying IgLON5 autoimmunity Serial brain MRI of the patient with.

Figure 1 Imaging and histopathologic characteristics of patients with CNS-FHL Imaging and histopathologic characteristics of patients with CNS-FHL FLAIR.

Coronal (A) and axial (B) contrast-enhanced T1-weighted MR images and an axial DWI (C) and ADC map (D) in a patient with primary dural B-cell lymphoma.

Castleman's disease presenting as a midline neck mass

Off-midline non-contrast-enhanced sagittal T1-weighted MR image (600/12/1) in a 48-year-old woman with breast cancer who presented with headache and fatigue.

A 56-year-old man with fever for 1 week.

(A) Axial FLAIR MRI reveals multiple areas of high signal intensity (arrows) in leptomeninges. (A) Axial FLAIR MRI reveals multiple areas of high signal.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Chronic CNS-IRIS without coinfection.

Presentation transcript:

Figure 4 New PET radiotracers in lymphoma Figure 4 | New PET radiotracers in lymphoma. a–f | Synchronous images of a patient with diffuse large B-cell lymphoma of the CNS of the germinal centre B-cell (GCB)-like phenotype. a | Contrast-enhanced coronal MRI of a patient with a midline lymphomatous mass. b | Coronal PET image showing physiological FDG–PET uptake in the CNS, which reduces the accuracy of lesion detection. c–f | Multiple short-interval relapses (subsequent to complete responses on both MRI and [18F]fluoromethylcholine (FCH)–PET, images not shown), note the concordance of MRI and FCH–PET images in terms of lesion detection. g–i | Synchronous images of a patient with lymphoblastic lymphoma. g | Posterior coronal contrast-enhanced MRI image with diffuse dural infiltration and abnormal marrow signal. h | Fused FCH-PET–CT coronal image demonstrating abnormal dural tracer uptake (arrow). i | Fused FCH-PET–CT maximum intensity projection demonstrating diffuse marrow uptake (arrow). FCH–PET did not demonstrate any substantial prognostic power for response duration; efficacy of FCH–PET for leptomeningeal disease has not been evaluated. No published studies evaluating the performance of FCH–PET exist for patients with CNS lymphoma. Image series courtesy of B. Sharma and N. Tunariu, The Royal Marsden, London, UK. Cunningham, J. et al. (2017) Evolution of lymphoma staging and response evaluation: current limitations and future directions Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.78